212776-19-7

Basic information

• Product Name: trans 4-DiMethylaMinocrotonic Acid Methyl Ester
• Synonyms: trans 4-DiMethylaMinocrotonic Acid Methyl Ester;(2E)-4-(Dimethylamino)-2-butenoic acid methyl ester;(E)-4-(DiMethylaMino)-2-butenoic Acid Methyl Ester;(E)-4-(DiMethylaMino)but-2-enoic Acid Methyl Ester;Methyl (E)-4-(diMethylaMino)but-2-enoate
• CAS NO: 212776-19-7
• Molecular Formula: C₇H₁₃NO₂
• Molecular Weight: 143
• Product Categories: Amines;Intermediates & Fine Chemicals;Miscellaneous Reagents;Pharmaceuticals
• Mol File: 212776-19-7.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 176℃
• Flash Point: 63℃
• Appearance: /
• Density: 0.964
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• Solubility: Dichloromethane, Methanol
• PKA: 7.61±0.28(Predicted)
• CAS DataBase Reference: trans 4-DiMethylaMinocrotonic Acid Methyl Ester(CAS DataBase Reference)
• NIST Chemistry Reference: trans 4-DiMethylaMinocrotonic Acid Methyl Ester(212776-19-7)
• EPA Substance Registry System: trans 4-DiMethylaMinocrotonic Acid Methyl Ester(212776-19-7)

Safety Data

• Hazardous Substances Data: 212776-19-7(Hazardous Substances Data)

Usage

Chemical Properties

Orange Oil

Uses

Pelitinib intermediate.

Upstream product

• 1117-71-1 methyl-4-bromo-2-butenoate 
• 124-40-3 dimethyl amine 
• 506-59-2 N,N-dimethylammonium chloride 

Downstream Products

• 850140-72-6 afatinib 
• 1130155-48-4 (E)-4-(dimethylamino)-2-butenoic acid hydrochloride 

Relevant articles and documents

Chlorobenzene-pyridine compounds and application thereof

The invention relates to chlorobenzene-pyridine compounds and an application thereof. The compounds can be used for preparing a Smoothened protein inhibitor and a drug for resisting adenocarcinoma andesophagus cancer and have the structure in the general formula (I) shown in the description, wherein X is selected from the structure shown in the description, R1 is selected from H or the structureshown in the description, and R2 is selected from the structure shown in the description.

IDO INHIBITORS

There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.